{"url_path":"/sec/spro/8-k/2026-07-14/item-2-03","section_key":"item-2-03","section_title":"Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-302473-index.html","accession_number":"0001193125-26-302473","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-302473-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":45,"has_tables":true,"body_markdown":"Item 2.03\n\nCreation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.\n\nThe information set forth under “Royalty Financing Agreements” in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03."}